Frontiers in Immunology Vol. 15 (December issue) published our article “Ultrasensitive protein-level detection for respiratory infectious...

BioPhenoMA launches the ultra-sensitive PD-L1 detection reagent kit (Product Name: “PD-L1 TN-cyclon™ ELISA Kit”) for research use and...

Our engineer, Tatsuya Shima, will give a poster presentation at the 50th annual conference of the Society for Chemistry and Micro-Nano...

BioPhenoMA, Inc. (Shinjuku-Ku, Tokyo, Representative Director Daisuke Niwa, CEO Naoto Fujii) raised 190 million JPY from WASEDA...

We have entered into a research agreement with Chase Therapeutics (Washington D.C., USA), a startup focused on drug discovery, to develop...

A research collaboration with a Japanese manufacturer has been initiated for a blood biomarker test reagent for Alzheimer's disease....

We will be participating in BioJapan2024 and will have a booth and a presentation. Event Details: - BioJapan2024 will take place from...

Naoto Fujii, our CEO, is scheduled to take the stage from 4:22 p.m.. This event is a startup pitch event hosted by eathkey Inc.. You can...

Our company has been selected for the "NEXs Tokyo" overseas expansion support program (5th gen), an innovation creation project supported...

On July 26, Bio Asia Taiwan held GT-Vax Discovery Symposium, and our CEO will pitch on the stage.Come see us at Taipei Nangang Exhibition...

We will be presenting a booth at TOKYO REGIONAL2024 at Grand Hyatt Tokyo. Discover our technology in Startup Exhibition Room at the 2nd...

We will have a booth at "Frontier of Drug Discovery 2024" hosted by LINK-J on Monday, June 24. For more information, please visit...

The presentation will be made at "VENTURE PITCH Vol73" co-hosted by Nomura Securities on Thursday, June 20. https://vp73.peatix.com/?utm_...

Introduced in the Nikkei Biotech serial "Biotech Venture Exploration". https://bio.nikkeibp.co.jp/atcl/column/16/021500017/031500325/

On Sunday, March 17, we will participate in a career fair for researchers, salespeople, and managers of life science startups....

We joined i2.JP an open innovation network led by AstraZeneca. For more information, please visit the website https://www.i2jp.net/en/ind...

BioPhenoMA Inc. and Tokyo Medical University have established a collaborative research initiative to create novel biomarkers for...

Our company was featured on Nikkan Kogyo Shimbun newspaper on the subject of "Cancer growth would be caused by exosomes. BioPhenoMA has...

Our company was selected as one of the "53 Health Tech Startups Expected to Play an Active Role" by Nihon Keizai Shimbun (Nov 6th,...

At CHEMINAS 48 (Chemistry and Micro-Nano Systems Society) held in Kumamoto from November 6th to 8th, 2023 https://micro-nano.chips.jp/48/...